Table 1 Patient and tumor characteristics for IG-IMRT (n = 49) and RP followed by IMRT (n = 49)
Characteristics | Total | RP + IMRT | IG-IMRT | p-value |
|---|---|---|---|---|
(n = 98) | (n = 49) | (n = 49) | ||
Median age – years [range] | 66.8 [51.7-82.7] | 64.8 [51.7-82.7] | 70.2 [53.3-82.4] | < 0.001 £ |
Median follow-up – months [range] | 56.6 [18.22-115.1] | 51.5 [18.2-115.1] | 62.2 [25.5-106.0] | |
Clinical T stage | 1.0 $ | |||
T1c – n (%) | 60 (61.2%) | 30 (61.2%) | 30 (61.2%) | |
T2 – n (%) | 4 (4.1%) | 2 (4.1%) | 2 (4.1%) | |
T2a – n (%) | 14 (14.3%) | 7 (14.3%) | 7 (14.3%) | |
T2b – n (%) | 20 (20.4%) | 10 (20.4%) | 10 (20.4%) | |
Gleason score on biopsy | 1.0 μ | |||
≤ 6 – n (%) | 58 (59.2%) | 29 (59.2%) | 29 (59.2%) | |
7 – n (%) | 40 (40.8%) | 20 (40.8%) | 20 (40.8%) | |
Pretherapeutic PSA | 0.632 # | |||
Median value – ng/mL [range] | 8.7 [1.7 - 32] | 8.7 [2.7 - 29] | 8.7 [1.7 - 32] | |
Risk group | 1.0 $ | |||
Low | 30 (30.6%) | 15 (30.6%) | 15 (30.6%) | |
Intermediate | 62 (63.3%) | 31 (63.3%) | 31 (63.3%) | |
High | 6 (6.1%) | 3 (6.1%) | 3 (6.1%) | |
Concomitant hormones with radiation | 1.0 μ | |||
n (%) | 20 (20.4%) | 10 (20.4%) | 10 (20.4%) | |
Adjuvant hormones with radiation | 0.564 μ | |||
n (%) | 14 (14.3%) | 6 (12.2%) | 8 (16.3%) | |
Mean dose of radiotherapy | ||||
Prostatic fossa – median value (Gy) [range] | 70.0 [31.4 – 79.8] | 66.0 [31.4 – 70.3] | 77.4 [73.0 – 79.8] | < 0.001 # |
Rectum – median value (Gy) [range] | 38.1 [4.8 – 61.1] | 36.0 [4.8 – 57.1] | 39.3 [26.5 – 61.1] | 0.061 # |
Bladder – median value (Gy) [range] | 32.7 [15.5 – 67.3] | 43.6 [16.8 – 63.7] | 31.3 [15.5 – 67.3] | < 0.001 £ |